DSP
Why More Product Upstream Creates New Pressure Downstream
Pharma's Almanac
PAO-09-26-PA-15Sep 21, 2026
Enzymatic Synthesis
Transforming Enzymatic Processes into Commercial-Scale Manufacturing
Kohei Mori
Kaneka
PAO-09-26-CL-03Sep 18, 2026
Pathfinder
Platform Development vs. Molecule-Specific Process Development: Which Strategy Is Better for Biologics?
Nice Insight
PAO-26-PF-25Sep 18, 2026
Oncolytic Viruses
Manufacturing Oncolytic Viruses: Where Complexity Demands Experience
Mathias Kahl
IDT Biologika
PAO-09-26-CL-01Sep 17, 2026
M&A
Kincell Bio and Cellipont Bioservices Merge to Form Kincellis Advanced Therapies
Kincellis Advanced Therapies
PR-09-26-03Sep 17, 2026
Biosimilars
The Global Division of Labor Behind the Coming Oncology Biosimilar Wave
Pharma's Almanac
PAO-09-26-PA-18Sep 15, 2026
Pathfinder
Enzymatic Synthesis vs. Fermentation for Biomanufacturing: Which Production Strategy Is Better?
Nice Insight
PAO-26-PF-24Sep 11, 2026
Partnership
Samsung Biologics Signs USD 262 Million Manufacturing Agreement with European Pharmaceutical Company
Samsung Biologics
PR-09-26-02Sep 10, 2026
Single-Use
The Changing Economics of Single-Use Biomanufacturing
Pharma's Almanac
PAO-09-26-PA-08Sep 10, 2026
Biologics Platform
Platform-Based Drug Substance Development: Applying Prior Knowledge Across Modalities
Mathias Kahl
IDT Biologika
PAO-08-26-CL-03Sep 9, 2026
CDMO Governance
The Governance Gap: Why Good CDMO Partnerships Still Fail
Pharma's Almanac
PAO-09-26-PA-07Sep 9, 2026
CDMO Consolidation
How Far Should CDMO Network Consolidation Go?
Pharma's Almanac
PAO-09-26-PA-06Sep 8, 2026
Child Formulation
The Pediatric Formulation Gap
Pharma's Almanac
PAO-09-26-PA-05Sep 7, 2026
Pathfinder
Conventional Peptide Synthesis vs. Recombinant Peptide Production: Which Manufacturing Strategy Is Better?
Nice Insight
PAO-26-PF-23Sep 4, 2026
Productivity
The Next Productivity Leap in Mammalian Cell Culture
Pharma's Almanac
PAO-09-26-PA-03Sep 3, 2026
Development CDMO
The Case for Earlier CDMO Involvement in Drug Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-02Sep 2, 2026
M&A
Samsung Biologics Publishes Prospectus for PolyPeptide Public Tender Offer
Samsung Biologics
PR-09-26-01Sep 1, 2026
Funding
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
Samsung Biologics
PR-08-26-03Sep 1, 2026
Capacity
Is the Bioreactor Arms Race Over?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-01Sep 1, 2026
Biologics
Commercial Thinking Begins in Clinical Phases
Mathias Kahl
IDT Biologika
PAO-08-26-CL-02Sep 1, 2026